NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
05/03/2026
Voltar para busca
Dado oficial do USPTO
VIBERZI
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
45
Atualização mais recente
24/03/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
15/12/2014
Data de registro
29/03/2016
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/03/2026
Última transação
24/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
800
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
14/12/2015
Primeiro uso no comércio
14/12/2015
Código do desenho
4
Tipo de titular
99
Localização do titular
DUBLIN, IE
Examinador
MCBRIDE, THEODORE M
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
ALLERGAN HOLDINGS UNLIMITED COMPANY
FURIEX PHARMACEUTICALS, LLC
Furiex Pharmaceuticals, Inc.
Representantes
Maryam Arastu AbbVie Inc.
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
OralTransdermalInjectable and Intravaginal Contraceptives; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the sensory organs; Pharmaceuticals and medicines for the central nervous system; Pharmaceuticals and medicines for the urogenital organs; Pharmaceuticals and medicines for the circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome ; Pharmaceutical preparations that supportencourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; AntibioticsAntifungalsAntivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's diseasedementiaAIDS-related dementiaCNSneurological disordersneurodegenerative disordersdepressionneuroprotective agent; antidepressants; antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Excluding pharmaceuticals for the diagnosis and/or treatment of diabetes
Publicações
Histórico de despachos e eventos da marca no USPTO.
45 publicações encontradas
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
05/03/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
05/03/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/03/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
09/12/2025
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
29/03/2025
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
19/07/2022
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
19/07/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
19/07/2022
E815
TEAS SECTION 8 & 15 RECEIVED
09/02/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
29/03/2021
A7OK
AMENDMENT UNDER SECTION 7 - PROCESSED
07/01/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/01/2021
ES7R
TEAS SECTION 7 REQUEST RECEIVED
06/10/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
06/10/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
06/10/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
06/10/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
06/10/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
06/10/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
10/08/2016
R.PR
REGISTERED-PRINCIPAL REGISTER
29/03/2016
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
25/02/2016
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
24/02/2016
SUPC
STATEMENT OF USE PROCESSING COMPLETE
06/02/2016
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
28/01/2016
IUAF
USE AMENDMENT FILED
15/12/2015
EISU
TEAS STATEMENT OF USE RECEIVED
15/12/2015
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
15/12/2015
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/11/2015
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
04/08/2015
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/06/2015
PUBO
PUBLISHED FOR OPPOSITION
09/06/2015
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/05/2015
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/05/2015
ALIE
ASSIGNED TO LIE
06/05/2015
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/04/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/04/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/04/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/04/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/03/2015
GNRT
NON-FINAL ACTION E-MAILED
27/03/2015
CNRT
NON-FINAL ACTION WRITTEN
27/03/2015
DOCK
ASSIGNED TO EXAMINER
25/03/2015
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/12/2014
NWAP
NEW APPLICATION ENTERED
18/12/2014
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VIBERZI ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.